Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Anxiety and depression are common in patients with severe chronic obstructive pulmonary disease (COPD). Frequently exacerbation's of breathlessness are associated with panic/fear and indeed this may be the main cause for the for hospital admission. Patients prone to a tendency to experience and communicate somatic distress in response to psychosocial stress and to seek medical help for it are top of the "frequent flyer" league, costing the health care economy dearly. This is a particular problem in Hull with the high levels of smoking and urban deprivation combining to place the city at the bottom of the Department of Health COPD league tables.

Our hypothesis is that an effective treatment for anxiety will reduce the number of episodes of hospital admission by reducing the panic/fear element of mild COPD exacerbation's thus allowing the patient time to access the existing community based support services.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hull and East Yorkshire Hospitals NHS Trust; Hull University Teaching Hospitals NHS Trust
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Male/females aged between 40-80 years.

• Previous diagnosis of COPD confirmed by the GOLD criteria.

• At least two previous admissions to hospital for acute exacerbation of COPD.

• Physician diagnosed anxiety

• At least Mild anxiety score on HADS and GAD-7

• On a stable therapeutic regimen for COPD for 8 weeks prior to inclusion

• Known history of cigarette smoking at least 10 pack yrs

• Willing and able to comply with study procedures

• Able to provide written informed consent to participate

Exclusion Criteria:

• Current or past diagnosis of asthma

• Long-term oxygen therapy

• Currently on treatment with anti-depressives

• Serious inter-current illness (eg lung cancer)

• One year survival considered unlikely

• Patients who have evidence of alcohol or drug abuse

• Participation in another clinical trial with an investigational drug in four weeks preceding the screening visit

• Clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus

• Known or suspected hypersensitivity to escitalopram